PASADENA, Calif.--(BUSINESS WIRE)--Sanguine Corporation (OTC Bulletin Board: SGNC), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells and numerous other areas requiring oxygen profusion, in collaboration with its FDA testing contractors and development team, received its meeting minutes letter from the FDA related to the Company’s regulatory approval path. The Company is pleased to announce that it is complete with its animal testing program and is preparing to complete the manufacturing process to support PHER-O2’s Master Drug File (MDF) submission to the FDA. Information related to Drug Master Files may be found at: http://www.fda.gov/cder/guidance/dmf.htm.
